Inclusion Criteria:

          1. Must have previously untreated multiple myeloma (MM) as defined by the IMWG criteria
             requiring treatment according to the investigator.

          2. Are appropriate candidates for either the VRd or Rd backbone antimyeloma therapy
             according to the investigator.

          3. Must have measurable disease defined by at least 1 of the following:

               -  Serum M-protein >=1 gram per deciliter (g/dL) (>=10 gram/liter [g/L]).

               -  Urine M-protein >=200 mg/24 h.

               -  Serum FLC assay: involved FLC level >=10 mg/dL (≥100 milligram per liter [mg/L])
                  provided the serum FLC ratio is abnormal.

          4. Participants receiving lenalidomide must be able to take concurrent prophylactic
             anticoagulation per standard clinical practice as directed by the investigator.

          5. Life expectancy >3 months.

          6. Eastern Cooperative Oncology Group (ECOG) performance status score less than or equal
             to (<=) 2.

        Exclusion Criteria:

          1. Prior systemic therapy for MM.

             o treatment with bisphosphonates or a single course of glucocorticoids does not
             disqualify the participant (the maximum dose of corticosteroids should not exceed the
             equivalent of 160 mg [for example, 40 milligram per day (mg/d) for 4 days] of
             dexamethasone).

          2. Current participation in another interventional study, including other clinical trials
             with investigational agents (including investigational vaccines or investigational
             medical device) within 4 weeks of the first dose of TAK-079 or any agent in the
             backbone regimen and throughout the duration of this trial.

          3. Prior radiation therapy within 14 days of the first dose of TAK-079 or any backbone
             regimen agents.

             NOTE: Prophylactic localized ("spot") radiation for areas of pain is allowed.

          4. Major surgery within 4 weeks before Cycle 1 Day 1 (kyphoplasty is not considered major
             surgery). Participants should be fully recovered from any surgically related
             complications.

          5. Plasmapheresis within 28 days of randomization.

          6. If plasmacytoma is the only measurable parameter for assessing disease response,
             participant is not eligible because of difficult response evaluation.

          7. Clinical signs of meningeal involvement of MM exhibited during screening.

          8. Serum positive for human immunodeficiency virus (HIV) or active hepatitis B virus
             (HBV) or hepatitis C virus (HCV) infection.

          9. Known severe allergic or anaphylactic reactions to human recombinant proteins or
             excipients used in the TAK-079 formulation or agents in the backbone regimen
             (lenalidomide, bortezomib, dexamethasone) as per the respective prescribing
             information or for TAK-079, as outlined in the current investigator's brochure (IB).

         10. Systemic infection requiring systemic antibiotic therapy or other serious infection
             within 14 days before the first dose of TAK-079 or any agent in the backbone regimen.
             Urinary tract infection is not considered a systemic infection.

         11. A 12-lead electrocardiogram (ECG) showing a QT interval corrected by Frederica's
             formula (QTcF) >470 milliseconds. If a machine reading is above this value, the ECG
             should be reviewed by a qualified reader and confirmed on a subsequent ECG.

         12. Diagnosis of primary amyloidosis, Waldenstrom's disease, monoclonal gammopathy of
             undetermined significance (MGUS) or smoldering multiple myeloma (SMM) per IMWG
             criteria or standard diagnostic criteria, plasma cell leukemia (according to the World
             Health Organization [WHO] criterion: >=20% of cells in the peripheral blood with an
             absolute plasma cell count of more than 2 *10^9/L), polyneuropathy, organomegaly,
             endocrinopathy, monoclonal gammopathy and skin changes (POEMS syndrome),
             myelodysplastic syndrome, or myeloproliferative syndrome.

         13. History of myelodysplastic syndrome or another malignancy other than MM, except for
             the following: any malignancy that has been in complete remission for 2 years,
             adequately treated local basal cell or squamous cell carcinoma of the skin, cervical
             carcinoma in situ, superficial bladder cancer, asymptomatic prostate cancer (Gleason
             score <=6 without known metastatic disease and with no requirement for therapy, or
             requiring only hormonal therapy and stable prostate-specific antigen for >=1 year
             before initiation of study therapy), breast carcinoma in situ with full surgical
             resection, and treated medullary or papillary thyroid cancer.